|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Schering-Plough |
|---|---|
| Collaborator: |
AESCA Pharma GmbH |
| Information provided by: | Schering-Plough |
| ClinicalTrials.gov Identifier: | NCT00279565 |
Purpose
This randomized, single-center, controlled study is designed to evaluate the safety, tolerability, and efficacy of treatment with Peg-Intron with Rebetol in methadone or buprenorphine maintenance patients with hepatitis C.
| Condition | Intervention | Phase |
|---|---|---|
|
Hepatitis C, Chronic |
Drug: buprenorphine Drug: methadone Drug: pegylated interferon alfa-2b plus ribavirin |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Randomized, Controlled Study of Buprenorphine and Methadone in Hepatitis C Patients in Need of Treatment |
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Lab parameters:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | P04279 |
| Study First Received: | January 17, 2006 |
| Last Updated: | February 28, 2007 |
| ClinicalTrials.gov Identifier: | NCT00279565 History of Changes |
| Health Authority: | Austria: Federal Ministry for Health and Women |
|
buprenorphine methadone Peg-Intron Rebetol |
|
Respiratory System Agents Anti-Infective Agents Liver Diseases Hepatitis, Chronic Flaviviridae Infections Immunologic Factors Antineoplastic Agents Narcotic Antagonists Physiological Effects of Drugs Hepatitis, Viral, Human Buprenorphine Sensory System Agents Therapeutic Uses Analgesics Growth Inhibitors |
Hepatitis C Angiogenesis Modulating Agents Analgesics, Opioid Interferon-alpha RNA Virus Infections Growth Substances Central Nervous System Depressants Narcotics Antiviral Agents Angiogenesis Inhibitors Pharmacologic Actions Virus Diseases Hepatitis Methadone Digestive System Diseases |